Enliven Therapeutics Inc (ELVN)

Dec 21, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World

Dec 21, 2024

Dec 19, 2024

Wellington Management Group LLP Purchases 36,267 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat

Dec 19, 2024

Dec 17, 2024

Lord Abbett & CO. LLC Takes Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat

Dec 17, 2024

Dec 14, 2024

Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Simply Wall St

Dec 14, 2024

Dec 14, 2024

When the Price of (ELVN) Talks, People Listen - Stock Traders Daily

Dec 14, 2024

Dec 13, 2024

Enliven Therapeutics (NASDAQ:ELVN) Now Covered by BTIG Research - MarketBeat

Dec 13, 2024

Dec 12, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Acquired by Charles Schwab Investment Management Inc. - MarketBeat

Dec 12, 2024

Dec 12, 2024

Clear Street sets Enliven Therapeutics stock to buy with $36 target - Investing.com Canada

Dec 12, 2024

Dec 07, 2024

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 6.8%Should You Buy? - MarketBeat

Dec 07, 2024

Dec 07, 2024

Janus Henderson Group PLC Purchases 313,019 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat

Dec 07, 2024

Dec 05, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Sold by RA Capital Management L.P. - MarketBeat

Dec 05, 2024

Dec 04, 2024

Patient Square Capital LP Takes $2.31 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat

Dec 04, 2024

Dec 04, 2024

Walleye Capital LLC Takes $2.54 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat

Dec 04, 2024

Dec 04, 2024

Fmr LLC Boosts Holdings in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat

Dec 04, 2024

Dec 03, 2024

Enliven Therapeutics CFO Benjamin Hohl sells $130,688 in stock By Investing.com - Investing.com Canada

Dec 03, 2024

Dec 02, 2024

Enliven Therapeutics CFO Benjamin Hohl sells $130,688 in stock - Investing.com

Dec 02, 2024

Dec 02, 2024

Comparing Enliven Therapeutics (NASDAQ:ELVN) & Terns Pharmaceuticals (NASDAQ:TERN) - Defense World

Dec 02, 2024

Nov 30, 2024

Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 3%What's Next? - MarketBeat

Nov 30, 2024

Nov 28, 2024

Ally Bridge Group NY LLC Takes $6 Million Position in Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat

Nov 28, 2024

Nov 28, 2024

Acuta Capital Partners LLC Sells 101,330 Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) - MarketBeat

Nov 28, 2024

Nov 25, 2024

Enliven Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 - Marketscreener.com

Nov 25, 2024

Nov 22, 2024

(ELVN) Investment Analysis - Stock Traders Daily

Nov 22, 2024

Nov 21, 2024

Enliven Therapeutics to Present at the Jefferies London Healthca - GuruFocus.com

Nov 21, 2024

Nov 19, 2024

Short Interest in Enliven Therapeutics, Inc. (NASDAQ:ELVN) Increases By 6.1% - MarketBeat

Nov 19, 2024

Nov 19, 2024

Enliven Therapeutics, Inc. (NASDAQ:ELVN) Shares Bought by First Turn Management LLC - MarketBeat

Nov 19, 2024

Nov 19, 2024

Robert W. Baird Issues Positive Forecast for Enliven Therapeutics (NASDAQ:ELVN) Stock Price - Defense World

Nov 19, 2024

Nov 16, 2024

Enliven Therapeutics has cash runway into late 2026 - BizWest

Nov 16, 2024

Nov 15, 2024

Robert W. Baird Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock - MarketBeat

Nov 15, 2024

Nov 15, 2024

RA Capital Management, L.P. Reduces Stake in Enliven Therapeutics Inc. - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

COMMODORE CAPITAL LP Expands Stake in Enliven Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 15, 2024

Citadel Advisors LLC Adjusts Stake in Enliven Therapeutics Inc - GuruFocus.com

Nov 15, 2024

Nov 14, 2024

Enliven Therapeutics Reports Q3 Results and Clinical Progress - TipRanks

Nov 14, 2024

Nov 13, 2024

Polar Capital Holdings Plc's Strategic Acquisition in Enliven Th - GuruFocus.com

Nov 13, 2024

Nov 13, 2024

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - PR Newswire

Nov 13, 2024

Nov 11, 2024

(ELVN) Investment Analysis and Advice - Stock Traders Daily

Nov 11, 2024

Nov 07, 2024

Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - StockTitan

Nov 07, 2024

Nov 01, 2024

How to Take Advantage of moves in (ELVN) - Stock Traders Daily

Nov 01, 2024

Oct 31, 2024

Jones Trading Initiates Coverage of Enliven Therapeutics (ELVN) with Buy Recommendation - MSN

Oct 31, 2024

Oct 31, 2024

This Alumis Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Oct 31, 2024

Oct 31, 2024

Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 By Investing.com - Investing.com South Africa

Oct 31, 2024

Oct 30, 2024

Enliven Therapeutics CFO Benjamin Hohl sells shares worth $178,484 - Investing.com

Oct 30, 2024

Oct 27, 2024

Enliven Therapeutics (ELVN) Price Target Increased by 10.75% to 35.02 - MSN

Oct 27, 2024

Oct 23, 2024

Enliven Therapeutics chief medical officer sells $24,482 in stock - Investing.com India

Oct 23, 2024

Oct 22, 2024

Enliven Therapeutics CFO sells $24,422 in stock - Investing.com

Oct 22, 2024

Oct 22, 2024

Enliven Therapeutics chief medical officer sells $24,482 in stock By Investing.com - Investing.com Canada

Oct 22, 2024

Oct 22, 2024

Enliven Therapeutics COO Anish Patel sells $21,482 in stock - Investing.com

Oct 22, 2024

Oct 22, 2024

Enliven Therapeutics COO Anish Patel sells $21,482 in stock By Investing.com - Investing.com Australia

Oct 22, 2024

Oct 22, 2024

Enliven Therapeutics CFO sells $24,422 in stock By Investing.com - Investing.com Canada

Oct 22, 2024

Oct 22, 2024

Enliven Therapeutics' chief scientific officer sells $25,412 in stock By Investing.com - Investing.com Australia

Oct 22, 2024

Oct 22, 2024

Enliven Therapeutics CEO Kintz sells $27,722 in stock - Investing.com

Oct 22, 2024

Oct 22, 2024

Enliven Therapeutics' chief scientific officer sells $25,412 in stock - Investing.com India

Oct 22, 2024

Oct 22, 2024

Enliven Therapeutics director Heyman sells $47,104 in stock By Investing.com - Investing.com Australia

Oct 22, 2024